Christine T. Fischette, Ph.D.

Christine T. Fischette, Ph.D.

Executive Director

New York Office  |

Christine Fischette, Executive Director at Torreya, is a member of the Biotech and Pharma advisory teams. She brings over a quarter century of experience in corporate strategy and business development, as well as strong relationships with senior management within the BioPharma industry.

Before joining Torreya in 2015, Christine served as President of Enzo Therapeutics, Inc., a division of Enzo Biochem (NYSE: ENZ), and as Head of Negotiation, Global Business Development and Licensing for multi-billion-dollar therapeutic Business Franchise Boards at Novartis Pharmaceuticals. As a Board Director of Novartis’s General Medicine, Neuroscience, and Metabolic Disease Business units, she identified, negotiated, and executed multiple deals with US, European, Japanese, and Indian companies.

Christine also has held executive positions at Roche and at Pfizer, where she directed the entire drug development process and subsequent marketing effort for an anti-diabetes therapy, Glucotrol XL®, and subsequently became Head of Pfizer’s US commercial diabetes division. Prior to Pfizer, she was Senior Scientist at Hoffmann-La Roche, Inc. and at Rockefeller University, NY.

Dr. Fischette holds a Ph.D. in physiology from the University of Medicine & Dentistry of New Jersey, now Rutgers University, and has authored over 50 articles in peer-reviewed publications, including Science.

She is chair of the M&A committee for the USA/Canada Licensing Executive Society, co-chair for the Society’s New York chapter, BIO faculty member for the annual Fundamentals in Business Development Course, and an invited reviewer of grant proposals at Rockefeller University. Christine frequently organizes and speaks on BioPharma panels around the world, and she has served on private business and scientific advisory boards for therapeutics and devices.

Selected Transactions

License and Collaboration Agreement for Global Rights for LPA receptor Program with
Novo Nordisk
Up to $200 million
May 2018
License of
Gevokizumab and
certain associated IP to
$31 million upfront
August 2017